BACKGROUND: The Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) is a 7-year multicenter transfusion safety research initiative launched in 2011 by the National Heart, Lung, and Blood Institute. STUDY DESIGN AND METHODS: The domestic component involves four blood centers, 12 hospitals, a data coordinating center, and a central laboratory. The international component consists of distinct programs in Brazil, China, and South Africa, which involve US and in-country investigators. RESULTS: REDS-III is using two major methods to address key research priorities in blood banking and transfusion medicine. First, there will be numerous analyses of large "core" databases; the international programs have each constructed a donor and donation database while the domestic program has established a detailed research database that links data from blood donors and their donations, the components made from these donations, and data extracts from the electronic medical records of the recipients of these components. Second, there are more than 25 focused research protocols involving transfusion recipients, blood donors, or both that either are in progress or are scheduled to begin within the next 3 years. Areas of study include transfusion epidemiology and blood utilization, transfusion outcomes, noninfectious transfusion risks, human immunodeficiency virus-related safety issues (particularly in the international programs), emerging infectious agents, blood component quality, donor health and safety, and other donor issues. CONCLUSIONS: It is intended that REDS-III serve as an impetus for more widespread recipient and linked donor-recipient research in the United States as well as to help assure a safe and available blood supply in the United States and in international locations.
BACKGROUND: The Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) is a 7-year multicenter transfusion safety research initiative launched in 2011 by the National Heart, Lung, and Blood Institute. STUDY DESIGN AND METHODS: The domestic component involves four blood centers, 12 hospitals, a data coordinating center, and a central laboratory. The international component consists of distinct programs in Brazil, China, and South Africa, which involve US and in-country investigators. RESULTS: REDS-III is using two major methods to address key research priorities in blood banking and transfusion medicine. First, there will be numerous analyses of large "core" databases; the international programs have each constructed a donor and donation database while the domestic program has established a detailed research database that links data from blood donors and their donations, the components made from these donations, and data extracts from the electronic medical records of the recipients of these components. Second, there are more than 25 focused research protocols involving transfusion recipients, blood donors, or both that either are in progress or are scheduled to begin within the next 3 years. Areas of study include transfusion epidemiology and blood utilization, transfusion outcomes, noninfectious transfusion risks, human immunodeficiency virus-related safety issues (particularly in the international programs), emerging infectious agents, blood component quality, donor health and safety, and other donor issues. CONCLUSIONS: It is intended that REDS-III serve as an impetus for more widespread recipient and linked donor-recipient research in the United States as well as to help assure a safe and available blood supply in the United States and in international locations.
Authors: Pearl Toy; Ognjen Gajic; Peter Bacchetti; Mark R Looney; Michael A Gropper; Rolf Hubmayr; Clifford A Lowell; Philip J Norris; Edward L Murphy; Richard B Weiskopf; Gregory Wilson; Monique Koenigsberg; Deanna Lee; Randy Schuller; Ping Wu; Barbara Grimes; Manish J Gandhi; Jeffrey L Winters; David Mair; Nora Hirschler; Rosa Sanchez Rosen; Michael A Matthay Journal: Blood Date: 2011-11-23 Impact factor: 22.113
Authors: T F Zuck; R A Thomson; G B Schreiber; R O Gilcher; S H Kleinman; E L Murphy; H E Ownby; A E Williams; M P Busch; J W Smith Journal: Transfusion Date: 1995 Nov-Dec Impact factor: 3.157
Authors: Jinhua Xiang; Sarah L George; Sabina Wünschmann; Qing Chang; Donna Klinzman; Jack T Stapleton Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Nareg H Roubinian; Jeanne E Hendrickson; Darrell J Triulzi; Jerome L Gottschall; Michael Michalkiewicz; Dhuly Chowdhury; Daryl J Kor; Mark R Looney; Michael A Matthay; Steven H Kleinman; Donald Brambilla; Edward L Murphy Journal: Crit Care Med Date: 2018-04 Impact factor: 7.598
Authors: Tamir Kanias; Mars Stone; Grier P Page; Yuelong Guo; Stacy M Endres-Dighe; Marion C Lanteri; Bryan R Spencer; Ritchard G Cable; Darrell J Triulzi; Joseph E Kiss; Edward L Murphy; Steve Kleinman; Mark T Gladwin; Michael P Busch; Alan E Mast Journal: Transfusion Date: 2018-11-26 Impact factor: 3.157
Authors: Lesedi M Williams; Zhihua Qi; Ken Batai; Stanley Hooker; Nancy J Hall; Roberto F Machado; Alice Chen; Sally Campbell-Lee; Yongtao Guan; Rick Kittles; Neil A Hanchard Journal: Blood Adv Date: 2018-12-26
Authors: N H Roubinian; J E Hendrickson; D J Triulzi; J L Gottschall; D Chowdhury; D J Kor; M R Looney; M A Matthay; S H Kleinman; D Brambilla; E L Murphy Journal: Vox Sang Date: 2016-12-21 Impact factor: 2.144
Authors: Victoria L Campbell; LeAnn Nguyen; Elise Snoey; Christopher L McClurkan; Kerry J Laing; Lichun Dong; Alessandro Sette; Cecilia S Lindestam Arlehamn; Danny M Altmann; Rosemary J Boyton; Justin A Roby; Michael Gale; Mars Stone; Michael P Busch; Phillip J Norris; David M Koelle Journal: Immunohorizons Date: 2020-08-04